Epic Sciences

Press Releases


Circulating tumor cells (CTC) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples.

Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform selection of the next line of therapy. A new non-invasive approach developed by Epic Sciences may be as effective at biomarker characterization as invasive surgical biopsies for metastatic castration-resistant prostate cancer (mCRPC) patients.


Epic Sciences' platform capable of single cell CTC identification sequencing in late stage, metastatic cancer.

After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences’ no cell left behind® technology may help identify these important tumor cells and characterize how a patient’s tumors have evolved over time.


Epic Sciences to present at World CDx Boston 2015.

Epic Sciences, Inc. announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015.


Epic Sciences appoints Dave Henderson as chief information officer.

Epic Sciences, Inc. announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation.


Epic Sciences' Dr. Dena Marrinucci is recognized as an honoree of MIT Technology Review's annual Innovators Under 35 list.

Today, MIT Technology Review revealed its annual list of Innovators Under 35, which includes Epic Sciences' Dena Marrinucci, Ph.D., who has been recognized for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments.


Epic Sciences publication validates unbiased detection of circulating tumor cells (CTC) from a liquid biopsy.

Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company’s no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics.


Epic Sciences appoints Dr. Greg Critchfield to board of directors.

Epic Sciences, Inc. a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences' board of directors. As current chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc., Dr. Critchfield has more than 30 years of experience in the clinical pathology and diagnostics space.